Repligen
RGEN
167.22
-7.64
-4.37%
Repligen
US · RGEN
#1445 by market cap
Listed 1970
167.22
-7.64
-4.37%
Live - 5344 symbols - heartbeat 493s ago
· 2026-10-08 07:36
Pre-market
167.22
0.00%
After-hours
167.22
0.00%
Overnight
166.83
-0.23%
- Market cap
- 10.62B
- P/E (TTM)i
- 229.07
- P/Bi
- 5.03
- EPSi
- 0.86
- Div yieldi
- 0.00%
- 52W posi
- 68%
Reader sentiment
Are you bullish or bearish on RGEN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 8.47, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +16.36% YoY
Margins
- Gross margin
- 52.32%
- Operating margin
- 5.63%
- Net margin
- 6.62%
Key ratios & quality
- Enterprise valuei
- 10.41B
- Altman Z-Scorei
- 8.47
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 194.03M | 270.25M | 366.26M | 670.53M | 801.54M | 632.36M | 634.44M | 738.26M |
| Gross profit | 107.50M | 151.15M | 209.63M | 391.25M | 455.71M | 278.44M | 274.65M | 386.25M |
| Selling & admin expenses | 65.69M | 95.61M | 119.62M | 183.87M | 215.83M | 218.58M | 263.37M | 290.51M |
| Research & development | 15.82M | 19.45M | 20.18M | 34.27M | 43.94M | 42.72M | 43.20M | 54.18M |
| Operating profit | 25.99M | 36.08M | 69.82M | 173.11M | 195.94M | 17.13M | -31.92M | 41.56M |
| Pretax profit | 21.44M | 26.15M | 59.22M | 153.54M | 219.14M | 56.71M | -27.04M | 62.38M |
| Tax | 4.82M | 4.74M | -709.00K | 25.25M | 33.18M | 21.11M | -1.52M | 13.49M |
| Net profit | 16.62M | 21.41M | 59.93M | 128.29M | 185.96M | 35.60M | -25.51M | 48.89M |
| Basic EPS | 0 | 0 | 1 | 2 | 3 | 1 | 0 | 1 |
| Diluted EPS | 0.37 | 0.44 | 1.11 | 2.24 | 3.24 | 0.63 | -0.46 | 0.86 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 169.17M | 182.37M | 188.81M | 197.91M | 194.26M | 204.13M |
| Gross profit | 91.37M | 93.00M | 100.52M | 103.83M | 108.28M | 110.04M |
| Selling & admin expenses | 70.71M | 70.91M | 73.66M | 74.36M | 76.54M | 76.62M |
| Research & development | 12.11M | 13.97M | 14.18M | 13.12M | 14.46M | 14.42M |
| Operating profit | 8.55M | 8.12M | 12.68M | 16.35M | 17.29M | 19.00M |
| Pretax profit | 7.94M | 18.22M | 17.11M | 19.11M | 1.77M | 14.15M |
| Tax | 2.11M | 3.35M | 2.20M | 5.83M | -6.56M | 9.15M |
| Net profit | 5.83M | 14.87M | 14.91M | 13.29M | 8.33M | 5.01M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | 0.10 | 0.26 | 0.26 | 0.23 | 0.15 | 0.09 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 275.74M | 641.83M | 902.38M | 931.68M | 998.12M | 1.11B | 1.07B | 1.14B |
| Cash & ST investments | 193.82M | 528.39M | 717.29M | 603.81M | 623.76M | 751.32M | 757.36M | 767.63M |
| Inventory | 42.26M | 54.83M | 95.03M | 184.49M | 238.28M | 202.32M | 142.96M | 170.46M |
| Total assets | 774.62M | 1.40B | 1.90B | 2.36B | 2.53B | 2.83B | 2.83B | 2.95B |
| Total current liabilities | 129.84M | 48.31M | 318.96M | 375.26M | 404.20M | 164.94M | 126.79M | 135.83M |
| Short-term debt | 103.49M | 3.56M | 248.99M | 263.56M | 291.57M | 75.08M | 15.10M | 21.56M |
| Long-term debt | -- | 232.77M | -- | -- | -- | 510.14M | 525.57M | 542.21M |
| Total liabilities | 159,053,000.00 | 340,345,000.00 | 373,737,000.00 | 608,287,000.00 | 620,900,000.00 | 866,340,000.00 | 856,948,000.00 | 843,570,000.00 |
| Total equity | 615.57M | 1.06B | 1.53B | 1.75B | 1.91B | 1.96B | 1.97B | 2.11B |
| Retained earnings | -15.57M | 5.84M | 65.77M | 194.06M | 397.27M | 432.87M | 407.35M | 456.25M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 1.03B | 1.06B | 1.10B | 1.14B | 1.16B | 1.20B |
| Cash & ST investments | 697.23M | 708.86M | 748.75M | 767.63M | 784.53M | 810.45M |
| Inventory | 153.11M | 155.86M | 160.32M | 170.46M | 179.26M | 186.60M |
| Total assets | 2.85B | 2.90B | 2.92B | 2.95B | 2.93B | 2.95B |
| Total current liabilities | 152.00M | 123.01M | 131.14M | 135.83M | 126.21M | 132.66M |
| Short-term debt | 15.15M | 16.04M | 19.31M | 21.56M | 21.07M | 19.32M |
| Long-term debt | 529.61M | 533.73M | 537.93M | 542.21M | 546.59M | 551.05M |
| Total liabilities | 866,660,000.00 | 839,886,000.00 | 840,624,000.00 | 843,570,000.00 | 825,309,000.00 | 838,148,000.00 |
| Total equity | 1.99B | 2.06B | 2.08B | 2.11B | 2.11B | 2.11B |
| Retained earnings | 413.18M | 428.05M | 442.96M | 456.25M | 464.58M | 469.59M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 32.77M | 67.22M | 62.63M | 119.02M | 172.08M | 113.92M | 175.39M | 117.42M |
| Depreciation & amortization | 15.78M | 20.87M | 27.07M | 38.45M | 57.01M | 86.11M | 86.56M | 96.96M |
| Free cash flow | 18.73M | 44.06M | 36.28M | 47.74M | 38.74M | 74.93M | 142.49M | 91.69M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 320.71M | 297.78M | 0 | 0 | -14.39M | 0 | 0 |
| Ending cash balance | 193.82M | 537.41M | 717.29M | 603.81M | 523.46M | 751.32M | 757.36M | 566.02M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 15.01M | 28.61M | 48.10M | 25.70M | 28.30M | 32.77M |
| Depreciation & amortization | 23.19M | 24.77M | 24.41M | 24.59M | 24.54M | 23.77M |
| Free cash flow | 10.58M | 21.00M | 42.71M | 17.40M | 23.35M | 26.70M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 697.23M | 708.86M | 748.75M | 566.02M | 584.64M | 608.81M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 2.75 | 2.56 | 4.63 | 7.82 | 10.16 | 2.14 | -1.29 | 2.40 |
| ROA %i | 2.19 | 1.97 | 3.63 | 6.02 | 7.62 | 1.55 | -0.90 | 1.69 |
| ROIC %i | 3.09 | 2.52 | 4.40 | 7.09 | 8.40 | 1.71 | -0.22 | 2.41 |
| 5-year avg ROE %i | 6.75 | 5.75 | 5.08 | 5.04 | 5.58 | 5.40 | 4.63 | 4.18 |
| EBIT margin %i | 14.51 | 13.12 | 19.48 | 24.79 | 27.49 | 10.35 | -0.99 | 11.36 |
| FCF / sales %i | 9.65 | 16.30 | 9.91 | 7.12 | 4.83 | 11.73 | 22.46 | 12.42 |
| Current ratioi | 2.12 | 13.28 | 2.83 | 2.48 | 2.47 | 6.74 | 8.41 | 8.37 |
| Quick ratioi | 1.77 | 11.84 | 2.47 | 1.92 | 1.83 | 5.31 | 7.03 | 6.82 |
| Debt / assetsi | 13.36 | 18.81 | 14.47 | 15.52 | 16.71 | 25.14 | 24.25 | 23.39 |
| LT debt / equityi | -- | 24.51 | 1.73 | 5.86 | 6.88 | 32.41 | 34.02 | 31.74 |
| Interest coveragei | 4.20 | 3.81 | 5.88 | 13.08 | 189.59 | 33.87 | -0.30 | 3.90 |
| Revenue CAGR (3Y) %i | 32.43 | 37.24 | 37.39 | 51.19 | 43.68 | 19.97 | -1.83 | -2.70 |
| Net income CAGR (3Y) %i | 21.15 | 22.38 | 28.33 | 97.64 | 105.55 | -15.94 | -- | -35.94 |
| FCF CAGR (3Y) %i | 14.67 | 139.78 | 44.61 | 36.59 | -4.20 | 27.35 | 43.98 | 33.27 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -1.16 | -0.68 | 0.08 | 2.40 | 2.51 | 1.99 |
| ROA %i | -0.81 | -0.48 | 0.06 | 1.69 | 1.78 | 1.42 |
| ROIC %i | -0.24 | 0.11 | 0.69 | 2.41 | 2.61 | 2.13 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -0.28 | 1.13 | 3.69 | 11.36 | 10.23 | 9.46 |
| FCF / sales %i | 17.95 | 15.27 | 14.62 | 12.42 | 13.68 | 14.03 |
| Current ratioi | 6.79 | 8.59 | 8.36 | 8.37 | 9.20 | 9.05 |
| Quick ratioi | 5.56 | 7.04 | 6.85 | 6.82 | 7.42 | 7.30 |
| Debt / assetsi | 23.97 | 23.64 | 23.56 | 23.39 | 23.46 | 23.42 |
| LT debt / equityi | 33.67 | 32.50 | 32.14 | 31.74 | 31.66 | 31.80 |
| Interest coveragei | -0.09 | 0.36 | 1.22 | 3.90 | 3.57 | 3.35 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Filtration Products is the largest reported line at 46.86% of revenue, across 6 reported segments.
- Chromatography products follows at 25.41%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Filtration Products46.86%
Chromatography products25.41%
Proteins products15.37%
Process analytics products12.65%
Quote time 2026-10-08 07:36:04 · For reference only, not investment advice and not tailored to your situation.